

**PETITION FOR REVIVAL OF AN INTERNATIONAL APPLICATION FOR
PATENT DESIGNATING THE U.S. ABANDONED UNINTENTIONALLY
UNDER 37 CFR 1.137(b)**

PU4995USW

First named inventor: **Sarah S. BACUS et al**

International (PCT) Application No.: **PCT/US2003/012739**

U.S. Application No.:
(if known)

Filed: **24 April 2003**

Title: PREDICTIVE MARKERS IN CANCER THERAPY

Attention PCT Legal Staff
Box PCT
Assistant Commissioner for Patents
Washington, D.C. 22313-1450

The above-identified application became abandoned as to the United States because the fees and documents required by 35 U.S.C. 371(c) were not filed prior to the expiration of the time set in 37 CFR 1.495(b) or (c) as applicable. The date for the abandonment is the day after the date on which the 35 U.S.C. 371(c) requirements were due. See 37 CFR 1.495(h).

APPLICANT HEREBY PETITIONS FOR REVIVAL OF THIS APPLICATION

NOTE: A grantable petition requires the following items:

- (1) Petition fee
- (2) Proper reply
- (3) Terminal disclaimer with disclaimer fee required for all international applications having an international filing date before June 8, 1995; and
- (4) Statement that the entire delay was unintentional

1. Petition fee

Large entity – fee **\$ 1,500** (37 CFR 1.17(m)) –please charge our deposit account 07-1392 for this fee and any other fees associated with this petition.

2. Proper reply

A. The proper reply (the missing 35 U.S.C. 371(c) requirement(s) in the form of:
Transmittal Letter under 35 USC 371 with corresponding papers and fees (identify type of reply):

has been filed previously on _____
 is enclosed herewith

3. Terminal disclaimer with disclaimer fee

Since this international application has an international filing date on or after June 8, 1995, no terminal disclaimer is required.

A terminal disclaimer (and disclaimer fee (37CFR 1.20(d) of \$ _____ for a small entity or \$ _____ for other than a small entity) disclaiming the required period of time is enclosed herewith (see PCToSB/63)

4. **Statement.** The entire delay in filing the required reply from the due date for the required reply until the filing of a grantable petition under 37 CFR 1.137(b) was unintentional.

30 March 2005

Date

Virginia G. CAMPEN

Virginia G. CAMPEN (Reg. No. 37,092)

GlaxoSmithKline

Corporate Intellectual Property Dept

Five Moore Drive, PO Box 13398

Research Triangle Park, NC 27709

Telephone: 919-483-1012/Fax: 919-483-7988

Enclosures:

- Response
- Fee Payment
- Terminal Disclaimer
- Other (please identify)

Application under 35 U.S.C. 371 with corresponding papers including:
Transmittal Letter//US Drawings/Preliminary Amendment/Declarations/Copies of PCT Request/IB301/IB304/IB308

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

Applicant(s): Sarah S. BACUS et al.

10/529922

PU4995USw

Serial No.
To be assignedFiling Date
Concurrently

Examiner

Group Art Unit

Invention: PREDICTIVE MARKERS IN CANCER THERAPY

I hereby certify that the following correspondence:

PETITION FOR REVIVAL OF INTERNATIONAL APPLICATION FOR PATENT ABANDONED
UNINTENTIONALLY with NATIONAL PHASE APPLICATION UNDER 35 USC 371 attached

(Identify type of correspondence)

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

March 30, 2005
(Date)

Elaine Martens

(Typed or Printed Name of Person Mailing Correspondence)

Elaine Martens

EV332129925US)

("Express Mail" Mailing Label Number)

Documents sent in this filing to BOX PCT

ATTENTION: PCT LEGAL STAFF;

Cert of mailing=1, Post Card=1

Petition for Revival=1; Transmittal Letter=3

dec=15; Prelim Amend=2; US Drawings=9

Copy PCT Request/IB304/IB308/IB301=11

RECEIVED
1 APR 2005Legal Staff
International Division